News

POA Pharma GmbH, a pharmaceutical company based in Sprockhövel, successfully ran its Medical Nutrition Scholarship for the second year. This year, the scholarship extended the applicant pool to Austria and the German Market. The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such [...]

In the March 2024 issue of the German PKU related newspaper 'Hamburger Kaffeeklatsch', Johannes Röhr interviews POA Pharma about its company mission and PKU EASY Microtabs. For a German version of the interview, click here.

POA Pharma GmbH, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany.

PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.

The new PKU EASY Microtabs Plus product provides [...]

POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose® OGS.

POA Pharma’s parent company, Galen Limited, a global pharmaceutical company, and proud member of the Almac Group, has an existing, long standing in-licensing relationship with Penlan [...]

Move adds substantial new therapeutic areas and territories to Galen’s reach

Craigavon, N.I., 8 Jan 2020 - Galen, the privately owned global pharmaceutical sales and marketing company, today announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and [...]